SCHEMBL19974713

SCHEMBL19974713

Cc1ccc(S(=O)(=O)NC(C)C(=O)C(=O)NCC2CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.59
HSD17B10 Q99714 2/20 0.53
TSHR P16473 2/20 0.53
HTT P42858 1/20 0.53
ALDH1A1 P00352 6/20 0.52
MEN1 O00255 2/20 0.52
CYP2C9 P11712 1/20 0.52
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 2/20 0.47
NPY5R Q15761 1/20 0.47
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
F2 P00734 1/20 0.44
PRSS1 P07477 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21176211 0.89 KMT2A (0.53) KMT2AALDH1A1MEN1LMNA
SCHEMBL19974846 0.89 KMT2A (0.47) KMT2AHSD17B10TSHRHTTALDH1A1
SCHEMBL19975409 0.89 GBA1 (0.51) KMT2AHSD17B10HTTALDH1A1MEN1
SCHEMBL21176241 0.83 KMT2A (0.46) KMT2AHSD17B10TSHRHTTALDH1A1
SCHEMBL19975391 0.81 ITGAV (0.45) KMT2AHTTALDH1A1KDM4ELMNA
SCHEMBL19974744 0.79 KMT2A (0.64) KMT2AHSD17B10TSHRHTTALDH1A1
SCHEMBL19975110 0.77 KMT2A (0.46) KMT2AALDH1A1MEN1NPY5RMAPT
SCHEMBL21183574 0.77 MAPK14 (0.50) KMT2AALDH1A1MEN1CYP2C9HPGD
SCHEMBL19974751 0.75 ITGAV (0.47) KMT2AHSD17B10ALDH1A1MEN1HPGD
SCHEMBL21176234 0.74 GBA1 (0.49) KMT2AALDH1A1MEN1HPGDNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885HSD17B10 2146/4885TSHR 4378/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885HSD17B10 2290/4885TSHR 4240/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885HSD17B10 2146/4885TSHR 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.